Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -44.47% is 73% above its 5-year average of -167.04%, near the high end of its 5-year range (-441.01%–-18.82%).
4.33% below its 12-month average of -42.63%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.57%.
RETURN ON ASSETS (ROA)
-44.47%
RETURN ON ASSETS (ROA) AVG TTM
-42.63%
RETURN ON ASSETS (ROA) AVG 3Y
-230.85%
RETURN ON ASSETS (ROA) AVG 5Y
-167.04%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-4.33%
CURRENT VS 3Y AVG
+80.74%
CURRENT VS 5Y AVG
+73.38%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.48%
median of 786 covered companies
CURRENT VS SECTOR MEDIAN
-41.29%
vs the sector median at left
Kalaris Therapeutics Inc
Market Cap
$61.12M
Return on Assets (ROA)
-44.47%
TTM Avg
-42.63%
3Y Avg
-230.85%
5Y Avg
-167.04%
Market Cap
$60.11M
Return on Assets (ROA)
-66.80%
TTM Avg
-56.95%
3Y Avg
-50.95%
5Y Avg
-40.99%
Market Cap
$60.49M
Return on Assets (ROA)
-14.15%
TTM Avg
-52.30%
3Y Avg
-73.34%
5Y Avg
-79.94%
Market Cap
$60.05M
Return on Assets (ROA)
-98.94%
TTM Avg
-57.19%
3Y Avg
-57.75%
5Y Avg
-128.29%
Market Cap
$59.91M
Return on Assets (ROA)
-393.68%
TTM Avg
-194.68%
3Y Avg
-123.06%
5Y Avg
-102.52%
Market Cap
$63.16M
Return on Assets (ROA)
-48.60%
TTM Avg
-59.64%
3Y Avg
-46.49%
5Y Avg
-40.66%
Market Cap
$63.23M
Return on Assets (ROA)
-39.17%
TTM Avg
-30.96%
3Y Avg
-31.81%
5Y Avg
-21.33%
Market Cap
$58.99M
Return on Assets (ROA)
-118.15%
TTM Avg
-138.13%
3Y Avg
-224.99%
5Y Avg
-221.92%
Market Cap
$59.89M
Return on Assets (ROA)
-128.88%
TTM Avg
-89.84%
3Y Avg
-89.26%
5Y Avg
-80.42%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kalaris Therapeutics Inc (KLRS) | $61.12M | -44.47% | -42.63% | -230.85% | -167.04% |
| Adicet Bio, Inc. (ACET)vs › | $60.11M | -66.80% | -56.95% | -50.95% | -40.99% |
| Xilio Therapeutics, Inc. (XLO)vs › | $60.49M | -14.15% | -52.30% | -73.34% | -79.94% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $60.05M | -98.94% | -57.19% | -57.75% | -128.29% |
| Oncolytics Biotech Inc. (ONCY)vs › | $59.91M | -393.68% | -194.68% | -123.06% | -102.52% |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.16M | -48.60% | -59.64% | -46.49% | -40.66% |
| Alps Group Inc (ALPS)vs › | $63.23M | -39.17% | -30.96% | -31.81% | -21.33% |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.99M | -118.15% | -138.13% | -224.99% | -221.92% |
| Fractyl Health, Inc. (GUTS)vs › | $59.89M | -128.88% | -89.84% | -89.26% | -80.42% |
| RenovoRx, Inc. (RNXT)vs › | $64.43M | -107.09% | -123.27% | -270.15% | -219.64% |
ROA
-44.5%
ROE
-76.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -35.68% |
| 2024-12-31 | -49.57% |
| 2023-12-31 | -441.01% |
| 2022-12-31 | -397.15% |
| 2021-12-31 | -60.00% |
| 2020-12-31 | -18.82% |
| 2019-12-31 | -17.10% |
| 2018-12-31 | -9.60% |
